Key Speakers
Key Speakers
Dr. Nabil G. Seidah
The implication of the proprotein convertases PCSK9 and PCSK7 in lipid metabolism:
is there a connection to cancer/metastasis?
Dr. Seidah obtained his BSc in 1969 from Cairo University in Egypt, and his PhD in 1973 from Georgetown University, USA. Since 1983, Dr. Seidah is the director of Laboratory of Biochemical Neuroendocrinology of IRCM. Dr Seidah is the recipient of several awards, including the Royal Society of Canada, the Order of Quebec and the Order of Canada. In 2011, he was awarded the Wilder Penfield prize for the best scientist in Quebec working in the biomedical field.
Professor Nima Rezaei
Inborn Errors of Immunity and Cancer: From Clinics to Genetics
Dr. Reza Malekzadeh
Genetic basis of premature mortality, gastrointestinal and urinary bladder cancer in Iran
Former Minister of Health and Medical Education of Iran. Distinguished Professor of Medicine, Digestive Disease Research Institute. Tehran University of Medical Sciences. Dr. Malekzadeh has received many awards, including the Medal of Honor from International Agency for Research on cancer (IARC/WHO) for outstanding contribution in research on cancer (2018).
Dr. Marjan Yaghmaie
Clinical implications of molecular tumor profiling in metastatic breast cancer patients
Dr. Amineh Vaghefi
The Impact of percision oncology and the barriers to overcome
Dr. Mohammad Amin Moosavi
Autophagy in cancer: challenges and therapeutic opportunities
Dr. Seyed Mahdi Jafarnejad
Dysregulated mRNA Translation Initiation in Cancer
Mehdi received his PhD in Experimental Medicine from The University of British Columbia in 2012, investigating the mechanisms of dysregulated microRNA biogenesis in melanomas. This was followed by a postdoctoral training stint at Goodman Cancer Centre at McGill University, studying the mechanisms of post-transcriptional regulation of gene expression. He joined the Patrick Johnston Centre for Cancer Research at Queen’s University Belfast in 2019 as a Principal Investigator. His group currently focuses on mechanisms of regulation of mRNA translation and decay, alterations in these mechanisms in cancer, and how these mechanisms contribute to therapy-resistance in cancer.Conference in Iran in 2019.
Dr. Davood Bashash
The PI3K signaling axis and its implication in human malignancies
Dr. Bashash achieved his Ph.D. in hematology from Tehran University of Medical Science. Then he completed a fellowship in Clinical Laboratory Sciences at Iran University of Medical Science. He is also the research manager of the National Institute for Medical Research Development (NIMAD).
Dr. Sina Salari
Curing cancer from within: the promise of cell therapy
Doctor Sina Salari completed his specialty training in Internal Medicine at Tehran University and completed his 3 years fellowship in Hematology and Oncology at Shahid Beheshti Medical University. Between 2013 to 2019 he was the Director of the deputy of treatment of the Oncology-Hematology and BMT department, and Head of the internal department and responsible authorized physician of Ayatollah Taleghani Hospital. Dr.Salari has a particular interest in cell therapy and treatment of gastrointestinal malignancies. He is a member of the Iranian Cancer-Immunotherapy scientific committee and organized the first cancer Immunotherapy Conference in Iran in 2019.
Dr. Yasser Riazalhosseini
Harnessing genomic data for precision medicine in renal cell carcinoma
Yasser Riazalhosseini undertook his doctoral and post-doctoral training at the German Cancer Research Centre (DKFZ) in Heidelberg, Germany. At DKFZ, he developed systems biology approaches that combine genomics datasets from hundreds of cancers coupled with detailed clinical data, and high-throughput functional studies. In 2012, Dr. Riazalhosseini joined the Department of Human Genetics at McGill, and was appointed Group Head of the Cancer Genomics program at the McGill Genome Centre. His group pioneered genomic characterization of renal cell carcinoma (RCC) through integrative analysis of genome and transcriptome sequencing data in the context of the International Cancer Genome Consortium (ICGC).
Dr. Mahya Mehrmohamadi
Early detection of cancer using epigenomics of cell-free DNA
Lead, Cancer Detection Team, Pardis Gene Inc. . Consulting Scientist, Genapsys Inc. , Redwood City, California. Assistant professor, University of Tehran, Iran. Postdoctoral Fellow, Stanford Cancer Institute. Ph.D. in Genetics and Genomics, Cornell University. Computer lab instructor, Cornell University. Ranked 4th in Iran’s national college entrance exam among more than 250,000 applicant.
Dr. Lucia Altucci
Targeting epigenome against cancer
Lucia Alltucci is Full Professor of General Pathology at the University of Campania Luigi Vanvitelli and she is the Rector’s Delegate for Research. She is an MD,PhD with a specialisation in medical oncology. She is the elected President of all Italian Pathologists.Her contribution to the understanding of chromatin deregulation and epi-biomarkers in cancer as well as to the identification of innovative epi-strategies for cancer treatment and prevention are considered relevant. She is Co-Editor in chief in the Clinical Epigenetics (Springer Nature) and Co-Editor in chief in the Epigenetics Communications (Springer Nature). She is member of the Traslational medicine PhD program which is constantly recruiting international candidates with a dedicated program for young women sci
Dr. Ernesto Picardi
Profiling the non-transient side of the epitranscriptome
Ernesto Picardi is Full Professor in Molecular Biology at the University of Bari (Italy) and Research Associate at the Institute of Biomembranes and Bioenergetics (IBBE) of the National Research Council (CNR). He developed the first methodology to predict de novo RNA editing events by RNAseq data from Illumina as well as SOLiD platforms, and maintains the largest RNA editing collection in humans (REDIportal).
Dr. Daniela Taverna
miR-214 as coordinator of tumor-stroma crosstalk during cancer progression and as therapeutic target
Daniela Taverna has been carrying out research on neoplastic progression for more than thirty years, focusing on the identification of alterations that induce tumor cells to become aggressive and form metastases in distant organs. More recently her lab has generated molecular tools, called chimeric aptamers, able to target specific microRNAs responsible for metastasis. In Torino she worked first at the Institute for Cancer Research and Treatment (IRCCS) in Candiolo, then at Molecular Biotechnology Center (MBC), within the Department of Molecular Biotechnology and Health Sciences (DBMSS), where she still works now.
Dr. Salvatore Oliviero
DNA methylation specificity in Develeopment and Cancer
Salvatore Oliviero is Professor in Molecular Biology at the University of Torino and head of the Laboratory of Epigenetomics at the Italian Institute for Genomic Medicine (IIGM) in Candiolo. From 2010 in Torino his lab focused on the regulation and function of DNA methylation in embryonic stem cells and in tumours. The main results of these studies led to the dissection of the functional interplay between the DNMTs and the Polycomb PRC2 complex to regulate the DNA methylation of developmental genes. The characterization of the DNA methylation dynamics in development and tumours.
Dr. Amir Hossein Saeidian
Whole Genome Sequencing for Molecular Diagnosis: Single vs Dual Genetic Disorders in Pediatric Cases with Multiple Congenital Abnormalities and Cancers
Dr. Saeidian completed his Ph.D. in Genetics, Genomics, and Cancer Biology with Dr. Jouni Uitto. His research focused on utilizing RNA sequencing in molecular diagnosis and virome profiling. Furthermore, he was involved in the discovery of multiple disease-causing genes. As a postdoctoral fellow at the Center for Applied Genomics (CAG), Children’s Hospital of Philadelphia, University of Pennsylvania with Dr. Hakon Hakonarson, he pursued his research in the field of molecular diagnostics with a focus on Whole Genome Sequencing. He will be an upcoming fellow in the Laboratory Genetics and Genomics fellowship.
Dr. Hassan Vahidnezhad
Whole-transcriptome sequencing for investigation of infection and carcinogenesis in the context of single-gene disorders
Hassan Vahidnezhad, Ph.D., is an Assistant Professor at the Department of Dermatology and Cutaneous and Biology at Thomas Jefferson University, Philadelphia, Pennsylvania. He is a medical geneticist by training, and his research has been focused on the molecular characterization of rare heritable skin disorders. He uses insights from patient-based genetics to reveal cellular pathways associated with disease etiology and aims to discover novel therapeutic targets for treating diseases. Recently, he focused on human genetic dissection or the susceptibility to persistent cutaneous HPV infections, also known as recalcitrant warts RW), which are very common and have been associated with the development of cutaneous warts and non-melanoma skin cancer.
Dr. Ali Sharifi Zarchi
How AI Will Revolutionise Cancer Genomics
Assistant Prof. of artificial intelligence and bioinformatics, Computer Engineering Department, Sharif University of Technology. Postdoc of bioinformatics, Colorado State University. Research associate of bioinformatics, Max Planck Institute for molecular biomedicine.Gold medal of the International Olympiad of Informatics.
Dr. Masoud Garshasbi
Developing NGS-based diagnostic tests for personalized cancer therapy
Member of scientific advisory team, Pardis Gene Inc. Associate professor in the Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. Ph.D. and Post-doc. in Human Molecular Genetics from Max Planck Institute for Molecular Genetics (MPIMG), Berlin, Germany. founder and head of the Medical Genetic Department at the DENA laboratory, Tehran, Iran. In Collaboration with Pardis Gene Company in developing several NGS-based diagnostic tests on cancer and other genetic disorders. Member of Iranian National Elites Foundation (INEF). Chosen as one of the first 50 distinguished Iranian researchers by the Iran Saramadane Elmi Federation (ISEF) in 2015.
